EP3953357
Efnasamsetningar og aðferðir við að meðhöndla sjúkdóma af völdum KIT og PDGFRA
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
8.4.2020EP published:
17.4.2024EP application number:
20721083.2
EP translation filed:
15.5.2024Grant published:
15.6.2024EPO information:
European Patent Register
Max expiry date:
7.4.2040Expiry date:
7.4.2026Next due date:
30.4.2026
Title in English:
PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASESLanguage of the patent:
English
Timeline
Today
8.4.2020EP application
17.4.2024EP Publication
15.5.2024Translation submitted
15.6.2024Registration published
7.4.2026Expires
Owner
Name:
Blueprint Medicines CorporationAddress:
45 Sidney Street, Cambridge, MA 02139, US
Inventor
Name:
KIM, Joseph, L.Address:
Cambridge, MA 02139, US
Name:
DINEEN, Thomas, A.Address:
Cambridge, MA 02139, US
Name:
GUZI, TimothyAddress:
Cambridge, MA 02139, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201962833529 PDate:
12.4.2019Country:
US
Number:
201962911016 PDate:
4.10.2019Country:
US
Number:
201962930240 PDate:
4.11.2019Country:
US
Classification
Categories:
C07D 487/04, A61P 35/00, A61K 31/53
Annual fees
Number
Paid
Expires
Payer
Number: 6
Paid: 14.3.2025
Expires: 7.4.2026
Payer: Árnason Faktor ehf.